Protagonist Therapeutics, Inc (NASDAQ:PTGX)
| Market Cap | 9.53B+148.3% |
| Revenue (ttm) | 281.99M+34.8% |
| Net Income | 82.91M+59.3% |
| EPS | 1.03+47.7% |
| Shares Out | 64.31M |
| PE Ratio | 121.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 478,019 |
| Open | 147.18 |
| Previous Close | 145.16 |
| Day's Range | 145.91 - 150.48 |
| 52-Week Range | 57.90 - 160.81 |
| Beta | 1.79 |
| Analysts | Buy |
| Price Target | 169.38(+14.31%) |
| Earnings Date | Nov 5, 2026 |
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PTGX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PTGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PTGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PTGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PTGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PTGX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PTGX
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $583.68M |
| VTIVanguard Morningstar Total Stock Market ETF | $280.41M |
| IWMiShares Russell 2000 ETF | $226.80M |
| VBVanguard Morningstar Small-Cap ETF | $202.07M |
| XBIState Street SPDR S&P Biotech ETF | $145.86M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $116.95M |
Estimated from each fund’s disclosed top holdings × AUM
PTGX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PTGX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score